Navigation Links
Reportlinker Adds Gene Therapy - technologies, markets and companies
Date:12/21/2010

therapy for genetic cardiovascular disorders 317

Genetic disorders predisposing to atherosclerosis 317

Familial hypercholesterolemia (FH) 317

Apolipoprotein E (apoE) deficiency 319

Hypertension 319

Genetic factors for myocardial infarction 320

Acquired cardiovascular diseases 320

Coronary artery disease with angina pectoris 320

Ad5FGF-4 320

Ischemic heart disease with myocardial infarction 321

Myocardial repair with IGF-1 therapy 322

Metalloproteinase-2 inhibitor gene therapy 322

Congestive heart failure 323

Rationale of gene therapy in CHF 323

Beta-ARKct gene therapy 323

Intracoronary adenovirus-mediated gene therapy for CHF 324

AAV-mediated gene transfer for CHF 324

AngioCell gene therapy for CHF 325

nNOS gene transfer in CHF 325

Cardiomyopathies 325

Cardiac conduction disturbances 326

Gene transfer approaches for biological pacemakers 326

Genetically engineered biological pacemakers 326

Gene therapy and heart transplantation 327

Peripheral arterial disease 327

Incidence and clinical features 327

Current management 328

Gene therapy for peripheral arterial disease 328

Angiogenesis by gene therapy 328

HIF-1a gene therapy for peripheral arterial disease 328

HGF gene therapy for peripheral arterial disease 329

Ischemic neuropathy secondary to peripheral arterial disease 329

Prevention of restenosis after angioplasty 330

Antisense approaches 330

Gene therapy to prevent restenosis after angioplasty 330

Techniques of gene therapy for restenosis 332

NOS gene therapy for restenosis 332

hTIMP-1 gene therapy to prevent intimal hyperplasia 333

Maintaining vascular patency after surgery 333

Companies involved in gene therapy of cardiovascular diseases 334

Future prospects of gene therapy of cardiovascu
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Reportlinker Adds Molecular Diagnostics - Technologies, Markets and Companies
2. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
3. Reportlinker Adds 2010 Membrane and Separation Technology Research Review
4. Reportlinker Adds Nanobiotechnology: Applications and Global Markets
5. Reportlinker Adds Chinese Markets for Biotechnology
6. Reportlinker Adds Merck KGaA: PharmaVitae Profile
7. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
8. Reportlinker Adds Global Anticoagulants Industry
9. Reportlinker Adds Global Specialty Enzymes Industry
10. Reportlinker Adds Biomarkers - Technologies, Markets And Companies
11. Reportlinker Adds Next Generation U.S. and E.U. Biomaterials/BioMedical Devices: Market Trends & Commercial Implications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Appleā€™s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, today ... has been added as a clinical trial site for ... patients with refractory glioblastoma multiforme (GBM), the most common ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... BioPharma Corp. (TSX, FSE: "HBP") today announced that John ... the BioFinance 2009 Investor Conference at 3:00 p.m. EDT ... Toronto. Mr. Docherty will provide an overview of ... its current product development programs, L-DOS47 and Topical Interferon ...
... Medical Corp (TSX: MS), a leading developer in the treatment of multiple ... present at BioFinance 2009 in Toronto., WHEN: Wednesday ... Eaton Centre Hotel (Trinity V room), ... Toronto, ON, About BioFinance ...
... Ltd, announced,today that it has been engaged by ... in,divesting its world class research centre, the IRBM, ... pharmaceutical,transactions experience in the healthcare and investment business ... and biological,discovery centre. IRBM has an outstanding record ...
Cached Biology Technology:Helix BioPharma to Present at the BioFinance 2009 Conference 2BioMS Medical to present at BioFinance 2009 2Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM 2
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... leading global STM publishers, has entered a publishing partnership ... Estuaries and Coasts. Appearing six times a year, ... on and management of estuarine and coastal ecosystems. ... 2008. The partnership will be officially announced at ...
... had megadroughts more extreme and widespread than any previously known ... now-lush tropical Africa was an arid scrubland during the early ... Africa and the evolution of fishes in Africa,s Great Lakes. ... the world, acts as a rain gauge," said lead scientist ...
... by an Indiana University environmental science professor and several ... corn has the potential to harm aquatic ecosystems. The ... journal Proceedings of the National Academies of Sciences ... assistant professor in the IU School of Public and ...
Cached Biology News:Estuarine Research Federation chooses Springer as publishing partner 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 3Newfound ancient African megadroughts may have driven the evolution of humans and fishes 4Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
...
Biology Products: